During the open enrollment period, it is extremely important that Medicare beneficiaries review their prescription coverage ...
AbbVie said on Friday the Trump administration was pushing for steeper cuts in this year's Medicare drug price negotiations, ...
5don MSN
FDA to streamline approvals for generic biological drugs in latest move targeting health costs
The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex ...
Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...
That’s why we need Senate Bill 41, authored by Sen. Scott Wiener, D-San Francisco, which will require a more fair and transparent pricing model for pharmacy benefit managers, the third-party companies ...
The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...
AbbVie recently announced positive topline results from its Phase 3b/4 SELECT-SWITCH trial, showing that Rinvoq (upadacitinib ...
The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...
AbbVie raised its 2025 profit forecast on Friday, after strong sales of newer immunology drugs Skyrizi and Rinvoq helped ...
(Reuters) - Amgen Inc's cheaper version of AbbVie's top-selling arthritis drug Humira is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback